Alex Philippidis is a Senior Business Editor at Inside Precision Medicine. He covers a diverse range of topics within medicine and healthcare, including healthcare technology, finance, and the evolving fields of cannabis and psychedelics. His work has been featured in notable publications such as Inside Precision Medicine and Genetic Engineering & Biotechnology News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Alex Philippidis mainly covers healthcare and pharmaceutical industry, focusing on investment analysis, private sector announcements, and press releases. He would likely be interested in receiving pitches related to breakthroughs in drug development, acquisitions within the biopharmaceutical industry, advancements in gene therapy as well as the application of AI in healthcare.
Given his interest in citing data and investment analysis, he might appreciate pitches that provide substantial data-driven insights into trends or companies within the healthcare and pharmaceutical sectors. Additionally, pitches featuring exclusive access to company executives for interviews or providing unique perspectives on M&A activities could also resonate with him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kevin Davies, Alex Philippidis
A journey that has lasted more than 30 years for Sangamo Therapeutics, a pioneering gene editing biotech company in the Bay Area, has reached an unwanted milestone as the company filed for Chapter 11 bankruptcy protection.
By: Alex Philippidis
SAN DIEGO—California's three life sciences clusters all lost jobs last year, yet the industry remains a major engine of innovation and economic growth, according to a report released by the state's largest life sciences organization to coincide with the Biotechnology Industry Organization (BIO) International Convention being held here.
By: Alex Philippidis
Merck KGaA, Darmstadt, Germany, has agreed to acquire Bio-Techne for approximately $11.3 billion, the companies said today, in a deal designed to position the buyer as more of a leader across the life science value chain by expanding its presence in high-growth, next-generation life-sci markets with Bio-Techne's tools, analytical technologies, and consumables.
By: Alex Philippidis
Insilico Medicine will partner with SK Biopharmaceuticals to discover new artificial intelligence (AI)-based drug candidates for disorders affecting the neuroimmune area of the central nervous system (CNS), through a collaboration that could generate up to $2.5 billion for the AI-based drug developer.
By: Alex Philippidis, Fay Lin, Corinna Singleman, Uduak Thomas
Credit: Thanakorn Phanthura / EyeEm / Getty Images More big biotech deals on the docket this week.
By: Alex Philippidis
Less than a month after its stock roller-coastered on safety signals associated with its late-stage ulcerative colitis (UC) drug candidate obefazimod, shares of Abivax (Euronext Paris and Nasdaq: ABVX) enjoyed smoother sailing this past week—namely a 63% surge in Europe and a 50% leap in the United States over four trading days, following more positive data that appeared to reassure investors.
By: Alex Philippidis
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, the companies said, in a deal that would expand the
By: Alex Philippidis
Novartis has agreed to acquire Myricx Bio, a London-based developer of next-generation antibody-drug conjugates (ADCs), for up to $1.5 billion in a deal designed to bolster the buyer's oncology pipeline with a next-generation ADC payload platform designed to fight cancer.
Total aggregate value of the drugs generating the highest sales in 2025 jumped 21.5% vs. 2024, and more than doubled from a decade ago
By: Alex Philippidis
Insilico Medicine (Hong Kong Exchange: 3696) , an AI-based drug developer whose profile within biopharma has risen with its recent collaborations with industry giants, has offered investors an upbeat revenue and profit forecast for the first half of 2026, driven by its series of partnerships and a wide-ranging pipeline whose first program has reached late-stage development this past week.
